Neonatal seizures: to treat or not to treat?

Area of Science:

• Neonatal neurology
• Neuroscience
• Pediatric epilepsy

Background:

• The neonatal brain's hyperexcitability is vital for development but increases seizure risk.
• Seizures are the most frequent neurological issue in neonates.
• While healthy neonatal brains tolerate seizures with minimal injury, compromised brains are more vulnerable.

Purpose of the Study:

• To highlight the risks associated with neonatal seizures, including impaired learning and increased future seizure susceptibility.
• To underscore the limitations of current conventional therapies for neonatal seizures.
• To explore potential novel therapeutic strategies, including AMPA antagonists, for improved seizure control and neuroprotection.

Main Methods:

• Review of existing literature on neonatal brain excitability and seizures.
• Analysis of the efficacy and limitations of conventional antiepileptic drugs (phenobarbital, phenytoin, benzodiazepines).
• Examination of emerging research on lidocaine and alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) antagonists like topiramate.

Main Results:

• Conventional therapies are frequently ineffective in controlling neonatal seizures.
• Lidocaine shows potential but requires further investigation.
• Animal studies suggest AMPA antagonists may offer neuroprotection, but safety concerns in neonates remain.

Conclusions:

• An aggressive approach to managing neonatal seizures is warranted due to potential long-term consequences.
• Existing treatments are insufficient, driving the need for alternative therapies.
• Excitatory amino acid antagonists show promise but require rigorous safety and efficacy studies in neonates to address neurodevelopmental concerns.